Compare · IRWD vs NVO
IRWD vs NVO
Side-by-side comparison of Ironwood Pharmaceuticals Inc. (IRWD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRWD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 350.7x IRWD ($635.4M).
- Over the past year, IRWD is up 397.7% and NVO is down 21.8% - IRWD leads by 419.5 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 2 for IRWD).
- NVO has more recent analyst coverage (25 ratings vs 14 for IRWD).
- Company
- Ironwood Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $3.85-0.77%
- $50.31-2.25%
- Market cap
- $635.4M
- $222.81B
- 1M return
- +4.90%
- +15.47%
- 1Y return
- +397.74%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2010
- News (4w)
- 2
- 5
- Recent ratings
- 14
- 25
Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IRWD
- Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
- PFO & PAO Silver Ronald sold $578,063 worth of shares (127,890 units at $4.52) as part of a pre-agreed trading plan, decreasing direct ownership by 29% to 313,680 units (SEC Form 4)
- Ironwood Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Shepard Jay was granted 63,481 shares, increasing direct ownership by 37% to 235,036 units (SEC Form 4)
- Director Kessler Marla L was granted 63,481 shares, increasing direct ownership by 38% to 229,364 units (SEC Form 4)
- Director Currie Mark G was granted 63,481 shares, increasing direct ownership by 10% to 676,900 units (SEC Form 4)
- Director Duane Jon R was granted 63,481 shares, increasing direct ownership by 33% to 253,820 units (SEC Form 4)
- Director Denner Alexander J was granted 67,546 shares, increasing direct ownership by 26% to 323,855 units (SEC Form 4)
- Director Mchugh Julie sold $80,460 worth of shares (21,571 units at $3.73) as part of a pre-agreed trading plan and was granted 63,481 shares, increasing direct ownership by 20% to 250,749 units (SEC Form 4)
- Director Moukheibir Catherine was granted 63,481 shares, increasing direct ownership by 54% to 181,425 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S